Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA

HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of Carevix™ from the U.S. Food and Drug Administration (FDA). ASPIVIX’s novel Cervical Stabilizer will allow millions of women across the USA access to significantly less painful treatments and IUD insertions.

Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant

We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally. 

hemotune raises CHF 7.25 million Series B1 funding

We are thrilled to share that HEMEX is part of the investment consortium financing the series B1 of hemotune AG. At HEMEX, we look forward to support hemotune on the journey to making the HemoSystem available to patients globally. 

Resistell AG announces completion of clinical pilot Performance Evaluation Study

We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.